Do analysts recommend YI or COSM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cosmos Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, YI or COSM?

111 has higher revenue and earnings than Cosmos Health. 111 is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $1.80B 0.02 -$9.65M -$1.60 N/A Cosmos Health $65.27M 0.59 -$19.15M -$0.64 N/A

Is YI or COSM more profitable?

111 has a net margin of -1.01% compared to Cosmos Health's net margin of -33.08%. 111's return on equity of 0.00% beat Cosmos Health's return on equity. Company Net Margins Return on Equity Return on Assets 111 -1.01% N/A -4.86% Cosmos Health -33.08% -56.88% -18.03%

Does the media favor YI or COSM?

In the previous week, 111 had 1 more articles in the media than Cosmos Health. MarketBeat recorded 5 mentions for 111 and 4 mentions for Cosmos Health. 111's average media sentiment score of 0.33 beat Cosmos Health's score of 0.10 indicating that 111 is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 111 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cosmos Health 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate YI or MEDS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Wellgistics Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, YI or MEDS?

111 has higher revenue and earnings than Wellgistics Health. 111 is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $1.80B 0.02 -$9.65M -$1.60 N/A Wellgistics Health $23.34M 0.50 -$101.28M -$46.13 N/A

Is YI or MEDS more profitable?

111 has a net margin of -1.01% compared to Wellgistics Health's net margin of -1,100.16%. Company Net Margins Return on Equity Return on Assets 111 -1.01% N/A -4.86% Wellgistics Health -1,100.16% N/A -171.81%

Does the media prefer YI or MEDS?

In the previous week, 111 had 3 more articles in the media than Wellgistics Health. MarketBeat recorded 5 mentions for 111 and 2 mentions for Wellgistics Health. Wellgistics Health's average media sentiment score of 0.35 beat 111's score of 0.33 indicating that Wellgistics Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 111 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Wellgistics Health 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend YI or RDGT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ridgetech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, YI or RDGT?

Ridgetech has lower revenue, but higher earnings than 111. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 111 $1.80B 0.02 -$9.65M -$1.60 N/A Ridgetech $132.16M 0.02 -$1.25M N/A N/A

Is YI or RDGT more profitable?

Ridgetech has a net margin of 0.00% compared to 111's net margin of -1.01%. Company Net Margins Return on Equity Return on Assets 111 -1.01% N/A -4.86% Ridgetech N/A N/A N/A

Does the media favor YI or RDGT?

In the previous week, 111 had 4 more articles in the media than Ridgetech. MarketBeat recorded 5 mentions for 111 and 1 mentions for Ridgetech. Ridgetech's average media sentiment score of 0.75 beat 111's score of 0.33 indicating that Ridgetech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 111 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ridgetech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend HKPD or YI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hong Kong Pharma Digital Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, HKPD or YI?

Hong Kong Pharma Digital Technology has higher earnings, but lower revenue than 111. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hong Kong Pharma Digital Technology $13.43M 0.13 -$1.14M N/A N/A 111 $1.80B 0.02 -$9.65M -$1.60 N/A

Is HKPD or YI more profitable?

Hong Kong Pharma Digital Technology has a net margin of 0.00% compared to 111's net margin of -1.01%. Company Net Margins Return on Equity Return on Assets Hong Kong Pharma Digital Technology N/A N/A N/A 111 -1.01% N/A -4.86%

Do analysts recommend MCK or YI?

McKesson currently has a consensus price target of $973.44, indicating a potential upside of 7.78%. Given McKesson's stronger consensus rating and higher possible upside, research analysts plainly believe McKesson is more favorable than 111. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score McKesson 0 Sell rating(s) 4 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.78 111 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, MCK or YI?

McKesson has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio McKesson $403.43B 0.26 $4.76B $37.37 24.17 111 $1.80B 0.02 -$9.65M -$1.60 N/A

Is MCK or YI more profitable?

McKesson has a net margin of 1.12% compared to 111's net margin of -1.01%. 111's return on equity of 0.00% beat McKesson's return on equity. Company Net Margins Return on Equity Return on Assets McKesson 1.12% -253.21% 5.90% 111 -1.01% N/A -4.86%

Does the media prefer MCK or YI?

In the previous week, McKesson had 12 more articles in the media than 111. MarketBeat recorded 17 mentions for McKesson and 5 mentions for 111. McKesson's average media sentiment score of 0.54 beat 111's score of 0.33 indicating that McKesson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment McKesson 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive 111 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

111 (YI) Competitors

$3.22 -0.09 (-2.72%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$3.22 0.00 (0.00%)

As of 10/2/2026 04:10 PM Eastern

Compare

YI vs. COSM, MEDS, RDGT, HKPD, and MCK

Should you buy 111 stock or one of its competitors? 111's main competitors and comparable companies include Cosmos Health (COSM), Wellgistics Health (MEDS), Ridgetech (RDGT), Hong Kong Pharma Digital Technology (HKPD), and McKesson (MCK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare distributors" industry.

How does 111 compare to Cosmos Health?

111 (NASDAQ:YI) and Cosmos Health (NASDAQ:COSM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

111 has higher revenue and earnings than Cosmos Health. 111 is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.80B	0.02	-$9.65M	-$1.60	N/A
Cosmos Health	$65.27M	0.59	-$19.15M	-$0.64	N/A

In the previous week, 111 had 1 more articles in the media than Cosmos Health. MarketBeat recorded 5 mentions for 111 and 4 mentions for Cosmos Health. 111's average media sentiment score of 0.33 beat Cosmos Health's score of 0.10 indicating that 111 is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
111	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cosmos Health	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

21.3% of 111 shares are owned by institutional investors. Comparatively, 12.6% of Cosmos Health shares are owned by institutional investors. 43.9% of 111 shares are owned by company insiders. Comparatively, 26.2% of Cosmos Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cosmos Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

111 has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Cosmos Health has a beta of 4.69, suggesting that its share price is 369% more volatile than the broader market.

111 has a net margin of -1.01% compared to Cosmos Health's net margin of -33.08%. 111's return on equity of 0.00% beat Cosmos Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
111	-1.01%	N/A	-4.86%
Cosmos Health	-33.08%	-56.88%	-18.03%

Summary

111 beats Cosmos Health on 9 of the 13 factors compared between the two stocks.

How does 111 compare to Wellgistics Health?

111 (NASDAQ:YI) and Wellgistics Health (NASDAQ:MEDS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

111 has a net margin of -1.01% compared to Wellgistics Health's net margin of -1,100.16%.

Company	Net Margins	Return on Equity	Return on Assets
111	-1.01%	N/A	-4.86%
Wellgistics Health	-1,100.16%	N/A	-171.81%

In the previous week, 111 had 3 more articles in the media than Wellgistics Health. MarketBeat recorded 5 mentions for 111 and 2 mentions for Wellgistics Health. Wellgistics Health's average media sentiment score of 0.35 beat 111's score of 0.33 indicating that Wellgistics Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
111	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Wellgistics Health	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Wellgistics Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

111 has higher revenue and earnings than Wellgistics Health. 111 is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.80B	0.02	-$9.65M	-$1.60	N/A
Wellgistics Health	$23.34M	0.50	-$101.28M	-$46.13	N/A

21.3% of 111 shares are owned by institutional investors. Comparatively, 5.7% of Wellgistics Health shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Comparatively, 29.1% of Wellgistics Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

111 has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Wellgistics Health has a beta of -3.51, meaning that its share price is 451% less volatile than the broader market.

Summary

111 beats Wellgistics Health on 9 of the 12 factors compared between the two stocks.

How does 111 compare to Ridgetech?

111 (NASDAQ:YI) and Ridgetech (NASDAQ:RDGT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Ridgetech has a net margin of 0.00% compared to 111's net margin of -1.01%.

Company	Net Margins	Return on Equity	Return on Assets
111	-1.01%	N/A	-4.86%
Ridgetech	N/A	N/A	N/A

21.3% of 111 shares are held by institutional investors. Comparatively, 45.3% of Ridgetech shares are held by institutional investors. 43.9% of 111 shares are held by company insiders. Comparatively, 22.6% of Ridgetech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ridgetech has lower revenue, but higher earnings than 111.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.80B	0.02	-$9.65M	-$1.60	N/A
Ridgetech	$132.16M	0.02	-$1.25M	N/A	N/A

111 has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Ridgetech has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ridgetech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, 111 had 4 more articles in the media than Ridgetech. MarketBeat recorded 5 mentions for 111 and 1 mentions for Ridgetech. Ridgetech's average media sentiment score of 0.75 beat 111's score of 0.33 indicating that Ridgetech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
111	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ridgetech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ridgetech beats 111 on 6 of the 10 factors compared between the two stocks.

How does 111 compare to Hong Kong Pharma Digital Technology?

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) and 111 (NASDAQ:YI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Hong Kong Pharma Digital Technology has a net margin of 0.00% compared to 111's net margin of -1.01%.

Company	Net Margins	Return on Equity	Return on Assets
Hong Kong Pharma Digital Technology	N/A	N/A	N/A
111	-1.01%	N/A	-4.86%

21.3% of 111 shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hong Kong Pharma Digital Technology has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, 111 has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Hong Kong Pharma Digital Technology has higher earnings, but lower revenue than 111.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hong Kong Pharma Digital Technology	$13.43M	0.13	-$1.14M	N/A	N/A
111	$1.80B	0.02	-$9.65M	-$1.60	N/A

In the previous week, 111 had 5 more articles in the media than Hong Kong Pharma Digital Technology. MarketBeat recorded 5 mentions for 111 and 0 mentions for Hong Kong Pharma Digital Technology. 111's average media sentiment score of 0.33 beat Hong Kong Pharma Digital Technology's score of 0.00 indicating that 111 is being referred to more favorably in the news media.

Company	Overall Sentiment
Hong Kong Pharma Digital Technology	Neutral
111	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hong Kong Pharma Digital Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Hong Kong Pharma Digital Technology and 111 tied by winning 5 of the 10 factors compared between the two stocks.

How does 111 compare to McKesson?

McKesson (NYSE:MCK) and 111 (NASDAQ:YI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

McKesson has higher revenue and earnings than 111. 111 is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
McKesson	$403.43B	0.26	$4.76B	$37.37	24.17
111	$1.80B	0.02	-$9.65M	-$1.60	N/A

McKesson has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, 111 has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

McKesson currently has a consensus price target of $973.44, indicating a potential upside of 7.78%. Given McKesson's stronger consensus rating and higher possible upside, research analysts plainly believe McKesson is more favorable than 111.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
McKesson	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
111	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

McKesson has a net margin of 1.12% compared to 111's net margin of -1.01%. 111's return on equity of 0.00% beat McKesson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
McKesson	1.12%	-253.21%	5.90%
111	-1.01%	N/A	-4.86%

85.1% of McKesson shares are held by institutional investors. Comparatively, 21.3% of 111 shares are held by institutional investors. 0.1% of McKesson shares are held by company insiders. Comparatively, 43.9% of 111 shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, McKesson had 12 more articles in the media than 111. MarketBeat recorded 17 mentions for McKesson and 5 mentions for 111. McKesson's average media sentiment score of 0.54 beat 111's score of 0.33 indicating that McKesson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
McKesson	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
111	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

McKesson beats 111 on 13 of the 16 factors compared between the two stocks.

Get 111 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YI vs. The Competition

Export

Metric	111	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.29M	$9.68B	$7.15B	$13.28B
Dividend Yield	N/A	2.61%	2.54%	17.33%
P/E Ratio	-2.01	34.21	275.67	26.04
Price / Sales	0.02	4.86	656.66	110.58
Price / Cash	N/A	120.59	78.87	52.62
Price / Book	-0.27	5.15	10.93	6.31
Net Income	-$9.65M	$315.68M	$3.51B	$362.16M
7 Day Performance	-15.60%	-2.59%	-2.00%	-1.66%
1 Month Performance	-7.36%	-3.07%	-6.19%	-4.68%
1 Year Performance	-28.44%	7.86%	8.03%	1.57%

111 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YI 111	0.5588 of 5 stars	$3.22 -2.7%	N/A	-28.4%	$28.29M	$1.80B	N/A	1,063
COSM Cosmos Health	1.9698 of 5 stars	$0.40 +12.6%	N/A	-64.8%	$40.05M	$65.27M	N/A	163	Gap Up
MEDS Wellgistics Health	0.2452 of 5 stars	$3.90 -8.9%	N/A	-89.2%	$12.48M	$23.34M	N/A	31	News Coverage Gap Down
RDGT Ridgetech	0.8845 of 5 stars	$0.93 +0.7%	N/A	-99.6%	$3.37M	$132.16M	N/A	980	Gap Up
HKPD Hong Kong Pharma Digital Technology	0.5588 of 5 stars	$0.12 -4.9%	N/A	-91.1%	$1.90M	$13.43M	N/A	11	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YI) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

111 (YI) Competitors